EP
ALNY icon

Essential Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Essential Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75.9K Buy
252
+152
+152% +$45.8K 0.04% 493
2026
Q1 		$33.1K Sell
100
-345
-78% -$117K 0.01% 733
2025
Q4 		$177K Sell
445
-791
-64% -$350K 0.05% 341
2025
Q3 		$564K Buy
1,236
+1,174
+1,894% +$478K 0.19% 152
2025
Q2 		$20.2K Buy
+62
New +$17.2K 0.01% 670

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Essential Partners's ALNY Position: Q2 2026 in Review

Essential Partners increased its Alnylam Pharmaceuticals (ALNY) stake by 152% in Q2 2026, buying an estimated $45.8K and bringing the position to 252 shares worth $75.9K. The position accounts for 0.04% of the portfolio, ranked #493.

Essential Partners first reported a position in ALNY in Q2 2025 and has held it in 5 quarters since. The position peaked at $564K in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Essential Partners held 252 shares of Alnylam Pharmaceuticals worth $75.9K as of Q2 2026.
  • Essential Partners bought 152 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $45.8K.
  • Alnylam Pharmaceuticals made up 0.04% of Essential Partners's portfolio in Q2 2026, its #493 holding.
  • Essential Partners first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Alnylam Pharmaceuticals position peaked at $564K in Q3 2025.
  • 788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.